

## Cabozantinib Therapy

### INDICATIONS FOR USE:

INDICATION	ICD10	Regimen Code	*Reimbursement Status
The treatment of advanced renal cell carcinoma (RCC) in adults following prior VEGF targeted therapy.	C64	00518a	02/01/2019

*\*If the reimbursement status is not defined<sup>1</sup>, the indication has yet to be assessed through the formal HSE reimbursement process.*

### TREATMENT:

The starting dose of the drugs detailed below may be adjusted downward by the prescribing clinician, using their independent medical judgement, to consider each patient's individual clinical circumstances.

Drug	Dose	Route	Cycle
Cabozantinib	60 mg once daily	PO Do not eat two hours prior or one hour after taking a dose	Continuous
Missed doses: If a patient misses a dose, the missed dose should not be taken if it is less than 12 hours before the next dose			

### ELIGIBILITY:

- Indications as above
- Advanced or metastatic renal-cell carcinoma with a clear cell component
- Aged 18 years or older
- ECOG 0-2
- Patients must have received prior treatment with at least one VEGFR-targeting tyrosine kinase inhibitor
- Adequate organ and marrow function

### EXCLUSIONS:

- Hypersensitivity to cabozantinib or any of the excipients
- Previous therapy with an mTOR inhibitor or cabozantinib

### PRESCRIPTIVE AUTHORITY:

The treatment plan must be initiated by a Consultant Medical Oncologist

### TESTS:

#### Baseline tests:

- FBC, renal, liver and bone profile
- Blood glucose
- Urinary Protein
- Thyroid Function
- Blood Pressure
- ECG

NCCP Regimen: Cabozantinib Therapy	Published: 02/01/19 Review: 02/01/21	Version number: 1
Tumour Group: Genitourinary NCCP Regimen Code: 00518	ISMO Contributor: Prof. Ray McDermott	Page 1 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

**Regular tests:**

- FBC, renal, liver and bone profile monthly
- Urinary protein monthly
- Thyroid function monthly
- Blood pressure monthly
- ECG as clinically indicated

**Disease monitoring:**

Disease monitoring should be in line with the patient’s treatment plan and any other test/s as directed by the supervising Consultant.

**DOSE MODIFICATIONS:**

- Any dose modification should be discussed with a Consultant
- Dose reductions are detailed in Table 1

**Table 1: Dose reductions for cabozantinib**

Dose Level	Dose
Starting Dose	60mg
First dose reduction	40mg
Second dose reduction	20mg
Third dose reduction	Discontinue

**Renal and Hepatic Impairment:**

**Table 2: Dose modification of cabozantinib in renal and hepatic impairment**

Renal Impairment	Dose	Hepatic Impairment	Dose
Mild/Moderate	Use with caution	Mild/Moderate	40mg once daily Monitor for adverse events and dose adjustment or treatment interruption should be considered as needed
Severe	Not recommended	Severe	Not recommended

NCCP Regimen: Cabozantinib Therapy	Published: 02/01/19 Review: 02/01/21	Version number: 1
Tumour Group: Genitourinary NCCP Regimen Code: 00518	ISMO Contributor: Prof. Ray McDermott	Page 2 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## Management of adverse events:

**Table 3: Dose Modification of cabozantinib for Adverse Events**

Adverse reactions	Recommended dose modification
Grade 1 and Grade 2 adverse reactions which are tolerable and easily managed	Dose adjustment is usually not required. Consider adding supportive care as indicated.
Grade 2 adverse reactions which are intolerable and cannot be managed with a dose reduction or supportive care	Interrupt treatment until the adverse reaction resolves to Grade $\leq 1$ . Add supportive care as indicated. Consider re-initiating at a reduced dose
Grade 3 adverse reactions (except clinically nonrelevant laboratory abnormalities)	Interrupt treatment until the adverse reaction resolves to Grade $\leq 1$ . Add supportive care as indicated. Re-initiate at a reduced dose
Grade 4 adverse reactions (except clinically nonrelevant laboratory abnormalities)	Interrupt treatment. Institute appropriate medical care. If adverse reaction resolves to Grade $\leq 1$ , re-initiate at a reduced dose. If adverse reaction does not resolve, permanently discontinue cabozantinib

## SUPPORTIVE CARE:

**EMETOGENIC POTENTIAL:** Minimal-Low (Refer to local policy).

**PREMEDICATIONS:** None

## OTHER SUPPORTIVE CARE:

No specific recommendations

## ADVERSE EFFECTS / REGIMEN SPECIFIC COMPLICATIONS

*The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details.*

As most events can occur early in the course of treatment, the physician should evaluate the patient closely during the first eight weeks of treatment to determine if dose modifications are warranted. Events that generally have early onset include hypocalcaemia, hypokalaemia, thrombocytopenia, hypertension, palmar-plantar erythrodysesthesia syndrome (PPES), proteinuria, and gastrointestinal (GI) events (abdominal pain, mucosal inflammation, constipation, diarrhoea, vomiting).

- **Hypertension** : Hypertension has been observed with cabozantinib. Blood pressure should be well-controlled prior to initiating cabozantinib. During treatment with cabozantinib, all patients should be monitored for hypertension and treated as needed with standard anti-hypertensive therapy. In the case of persistent hypertension despite use of anti-hypertensives, the cabozantinib dose should be reduced. Cabozantinib should be discontinued if hypertension is severe and persistent despite anti-hypertensive therapy and dose reduction of cabozantinib. In case of hypertensive crisis, cabozantinib should be discontinued.
- **Perforations and fistulas** : Serious gastrointestinal (GI) perforations and fistulas, sometimes fatal, have been observed with cabozantinib. Patients who have inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, peritonitis, diverticulitis, or appendicitis), have tumour infiltration in the GI tract, or have complications from prior GI surgery (particularly when associated

NCCP Regimen: Cabozantinib Therapy	Published: 02/01/19 Review: 02/01/21	Version number: 1
Tumour Group: Genitourinary NCCP Regimen Code: 00518	ISMO Contributor: Prof. Ray McDermott	Page 3 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

with delayed or incomplete healing) should be carefully evaluated before initiating cabozantinib therapy and subsequently they should be monitored closely for symptoms of perforations and fistulas including abscesses and sepsis. Persistent or recurring diarrhoea while on treatment may be a risk factor for the development of anal fistula. Cabozantinib should be discontinued in patients who experience a GI perforation or a fistula that cannot be adequately managed.

- **Thromboembolic events:** Events of venous thromboembolism, including pulmonary embolism, and events of arterial thromboembolism have been observed with cabozantinib. Cabozantinib should be used with caution in patients who are at risk for, or who have a history of, these events. Cabozantinib should be discontinued in patients who develop an acute myocardial infarction or any other clinically significant arterial thromboembolic complication.
- **Haemorrhage:** Severe haemorrhage has been observed with cabozantinib. Patients who have a history of severe bleeding prior to treatment initiation should be carefully evaluated before initiating cabozantinib therapy. Cabozantinib should not be administered to patients that have or are at risk for severe haemorrhage.
- **Proteinuria :** Urine protein should be monitored regularly during cabozantinib treatment. Cabozantinib should be discontinued in patients who develop nephrotic syndrome.
- **Wound complications:** Wound complications have been observed with cabozantinib. Cabozantinib treatment should be stopped at least 28 days prior to scheduled surgery, including dental surgery, if possible. The decision to resume cabozantinib therapy after surgery should be based on clinical judgment of adequate wound healing. Cabozantinib should be discontinued in patients with wound healing complications requiring medical intervention.
- **Prolongation of QT interval :** Cabozantinib should be used with caution in patients with a history of QT interval prolongation, patients who are taking antiarrhythmics, or patients with relevant pre-existing cardiac disease, bradycardia, or electrolyte disturbances. When using cabozantinib, periodic monitoring with on-treatment ECGs and electrolytes (serum calcium, potassium, and magnesium) should be considered.
- **Palmar-plantar erythrodysesthesia syndrome (PPES):** This has been observed with cabozantinib. When PPES is severe, interruption of treatment with cabozantinib should be considered. Cabozantinib should be restarted with a lower dose when PPES has been resolved to grade 1.
- **Reversible posterior leukoencephalopathy syndrome :** Reversible Posterior Leukoencephalopathy Syndrome (RPLS), also known as Posterior Reversible Encephalopathy Syndrome (PRES), has been observed with cabozantinib.

## DRUG INTERACTIONS:

- Concomitant medicinal products that are strong inhibitors of CYP3A4 should be used with caution, and chronic use of concomitant medicinal products that are strong inducers of CYP3A4 should be avoided. Selection of an alternative concomitant medicinal product with no or minimal potential to induce or inhibit CYP3A4 should be considered.
- Current drug interaction databases should be consulted for more information.

## ATC CODE:

Cabozantinib L01XE26

NCCP Regimen: Cabozantinib Therapy	Published: 02/01/19 Review: 02/01/21	Version number: 1
Tumour Group: Genitourinary NCCP Regimen Code: 00518	ISMO Contributor: Prof. Ray McDermott	Page 4 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		

## REFERENCES:

- 1 Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial; Lancet oncol.2016; 17(7): 917-927
- 2 Choueiri TK, Escudier B, Powles T et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma New Engl J Med 2015; 373: 1814-1823
- 3 Cabometyx SmPC, Accessed October 2018, Available at: [https://www.ema.europa.eu/documents/product-information/cabometyx-epar-product-information\\_en.pdf](https://www.ema.europa.eu/documents/product-information/cabometyx-epar-product-information_en.pdf)

Version	Date	Amendment	Approved By
1	18/12/2018		Prof Ray McDermott

Comments and feedback welcome at [oncologydrugs@cancercontrol.ie](mailto:oncologydrugs@cancercontrol.ie).

<sup>i</sup> ODMS – Oncology Drug Management System

CDS – Community Drug Schemes (CDS) including the High Tech arrangements of the PCRS community drug schemes

Further details on the Cancer Drug Management Programme is available at;

<http://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/>

NCCP Regimen: Cabozantinib Therapy	Published: 02/01/19 Review: 02/01/21	Version number: 1
Tumour Group: Genitourinary NCCP Regimen Code: 00518	ISMO Contributor: Prof. Ray McDermott	Page 5 of 5
<p>The information contained in this document is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use of these documents is the responsibility of the prescribing clinician, and is subject to HSE's terms of use available at <a href="http://www.hse.ie/eng/Disclaimer">http://www.hse.ie/eng/Disclaimer</a></p> <p><i>This information is valid only on the day of printing, for any updates please check <a href="http://www.hse.ie/NCCPchemoregimens">www.hse.ie/NCCPchemoregimens</a></i></p>		